Abstract
It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Graphical Abstract
Current Drug Targets
Title:Role of Interferons in Chronic Hepatitis C Infection
Volume: 18 Issue: 7
Author(s): Carolina Scagnolari, Katia Monteleone, Giulia Cacciotti and Guido Antonelli*
Affiliation:
- Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Viale di Porta Tiburtina 28 – 00185 Rome,Italy
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Abstract: It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Export Options
About this article
Cite this article as:
Scagnolari Carolina, Monteleone Katia, Cacciotti Giulia and Antonelli Guido*, Role of Interferons in Chronic Hepatitis C Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450117666160201112632
DOI https://dx.doi.org/10.2174/1389450117666160201112632 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy
Current HIV Research Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy
Anti-Cancer Agents in Medicinal Chemistry Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Molecular Targets for Modulating Lung Inflammation and Injury
Current Drug Targets Mediterranean Diet and Oxidation: Nuts and Olive Oil as Important Sources of Fat and Antioxidants
Current Topics in Medicinal Chemistry Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry Targeted Therapies for Advanced Non-Small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening An N-terminally Truncated Mutant of Human Chemokine CXCL14 has Biological Activity
Protein & Peptide Letters Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD
Current Medicinal Chemistry Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Innovative, Multifunctional Sequential Oligopeptide Carriers Socn-I and SOCn-II: Functions-Technology-Perspectives
Protein & Peptide Letters Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens
Current Drug Delivery Concanavalin A, from an Old Protein to Novel Candidate Anti-Neoplastic Drug
Current Molecular Pharmacology Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Acknowledgements to Reviewers:
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued)